| Literature DB >> 11740816 |
R J D'Amato1, S Lentzsch, K C Anderson, M S Rogers.
Abstract
We have explored the mechanism of the antiangiogenic effects of thalidomide by structure-activity studies. These investigations revealed that angiogenesis inhibition correlates with teratogenicity but not with tumor necrosis factor-alpha (TFA-alpha) inhibition. Additionally, one analog of thalidomide, 3-aminothalidomide, exhibited an unusual capacity to directly inhibit myeloma cell proliferation. This activity did not correlate with TNF-alpha inhibition. Thus 3-aminothalidomide was found to inhibit multiple myeloma through effects on both the tumor and vascular compartment. The effects of an inhibitor of both the tumor and vascular compartments of a tumor on tumor growth may be synergistic. Copyright 2001 by W.B. Saunders Company.Entities:
Mesh:
Substances:
Year: 2001 PMID: 11740816 DOI: 10.1053/sonc.2001.28601
Source DB: PubMed Journal: Semin Oncol ISSN: 0093-7754 Impact factor: 4.929